Valuation: BioRestorative Therapies, Inc.

Market Cap 2.97M 2.62M 2.48M 2.25M 4.21M 285M 4.26M 29.73M 11.46M 145M 11.15M 10.9M 468M P/E 2026 *
-0.24x
P/E 2027 * -0.29x
Enterprise Value 2.97M 2.62M 2.48M 2.25M 4.21M 285M 4.26M 29.73M 11.46M 145M 11.15M 10.9M 468M EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.28x
Free-Float
90.44%
Yield 2026 *
-
Yield 2027 * -
1 day+0.87%
1 week-8.63%
Current month-42.44%
1 month-41.49%
3 months-68.51%
6 months-60.80%
Current year-90.09%
1 week 2.26
Extreme 2.2601
2.69
1 month 2.26
Extreme 2.2601
4.2
Current year 2.26
Extreme 2.2601
25.6
1 year 2.26
Extreme 2.2601
34.6
3 years 2.26
Extreme 2.2601
73.4
5 years 2.26
Extreme 2.2601
480
10 years 2.26
Extreme 2.2601
400,800
Manager TitleAgeSince
Chief Executive Officer 28 27/08/2026
Director of Finance/CFO 38 27/08/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 28 12/06/2026
Director/Board Member 37 12/06/2026
Director/Board Member - 13/07/2026
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/25 Free

Chief Technology Officer

23,438 0.2938%
06/10/25 Free

Chief Executive Officer

27,344 0.3427%
14/02/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%-8.63%-91.97%-93.49% 2.97M
-0.70%-4.28%+52.62%+86.42% 71.53B
+0.14%+1.65%+37.65%+81.93% 60.12B
+4.77%+6.16%+36.77%+26.10% 27.98B
-1.73%-4.30%-18.37%+357.94% 25.25B
-0.51%-2.28%+0.48%-9.27% 24.76B
+0.80%+1.88%+21.14%-4.46% 20.99B
+3.46%+3.02%+158.90%+337.81% 15.54B
+0.48%+0.86%+44.56%+168.42% 14.53B
+2.96%+0.83%-5.25%+519.59% 14.41B
Average +1.05%-1.58%+23.65%+147.10% 27.51B
Weighted average by Cap. +0.57%-1.52%+36.67%+129.90%

Financials

2026 *2027 *
Net sales 1.4M 1.24M 1.17M 1.06M 1.99M 135M 2.01M 14.07M 5.42M 68.84M 5.28M 5.16M 222M 2.31M 2.04M 1.93M 1.75M 3.28M 222M 3.32M 23.16M 8.93M 113M 8.68M 8.49M 365M
Net income -13.52M -11.93M -11.29M -10.24M -19.2M -1.3B -19.39M -135M -52.21M -663M -50.78M -49.68M -2.13B -15.56M -13.73M -12.99M -11.78M -22.09M -1.49B -22.31M -156M -60.06M -762M -58.42M -57.15M -2.45B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
29/09/26 $2.330 +0.87% 15,079
28/09/26 $2.310 -9.41% 49,420
25/09/26 $2.550 +1.59% 29,435
24/09/26 $2.510 -3.46% 24,715
23/09/26 $2.600 +1.96% 85,219
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.330USD
Average target price
160.00USD
Spread / Average Target
+6,766.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock